3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
8
Ovarian Neoplasms
5
Prostatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
28
Trastuzumab
16
Paclitaxel
14
Docetaxel
12
Cyclophosphamide
11
Capecitabine
11
Nivolumab
9
fludarabine
7
Carboplatin
7
Oxaliplatin
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
Specimen Handling
5
Leucovorin
5
Irinotecan
5
Injections
5
Gemcitabine
5
Fluorouracil
5
Bevacizumab
5
atezolizumab
4
aldesleukin
4
Taxes
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Drug Therapy
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
zanidatamab
3
veliparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
rucaparib
×
Breast
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts